CHEK1 and pancreatic neoplasm: Urrutia et al. showed BRD4770 affected cell growth, DNA synthesis, cell cycle progression at S phase, and DNA-damage signaling, after combination with Checkpoint kinase1(Chk1) inhibitor prexasertib in pancreatic cancer [30].